Mar 14, 2023 / 12:30PM GMT
Peter Richard Lawson - Barclays Bank PLC, Research Division - Research Analyst
Good morning. My name is Peter Lawson. Welcome to Barclays Global Healthcare Conference in Miami. I'm really pleased to have with us -- up on the stage with us, Arcus. So we've got management team. We've got Terry Rosen, CEO, Co-Founder; and Jennifer Jarrett, COO.
Questions and Answers:
Peter Richard Lawson - Barclays Bank PLC, Research Division - Research AnalystAnd I guess the first question would be really around -- I guess you've answered this multiple times around ARC-7, kind of underperformance, kind of how you think about the -- your PD-1 versus other PD-1s. And I know this -- you've got some historical perspective as well around that and how those have changed over time.
Terry J. Rosen - Arcus Biosciences, Inc. - Co-Founder, Chairman & CEO
Sure. So we don't think the anti-PD-1 is underperforming in any way. We think zimberelimab, looks just like KEYTRUDA, looks like the other anti-PD-1s and without spending a ton of time
Trustpilot
